Fresenius offers international diversification, stable healthcare exposure, and upside from a strategic pivot. Find out why ...

Fresenius Kabi Canada, part of Fresenius group, announced the recent launch of Iodixanol Injection 270 and 320 for both the ...

Fresenius Medical Care (FME) has commenced the US commercialisation of its high-volume haemodiafiltration (HVHDF) kidney ...

Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second ...

Renalyx Health Systems launches AI-enabled dialysis machine RxT21 with real-time monitoring at ₹6.7 lakh, plans to scale ...

Fresenius Kabi's tocilizumab biosimilar Tyenne ® is the first and only tocilizumab biosimilar to be launched in Canada and is now commercially available for both subcutaneous and intravenous ...

Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient ...

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, presents new research and innovations at the 62nd Congress of the European ...

The Global Home Healthcare Market share is projected to be valued at USD 420.79 billion in 2024 and reach USD 666.91 billion ...